177 related articles for article (PubMed ID: 22400986)
21. Reduction in nicotine intake and oral mucosal changes among users of Swedish oral moist snuff after switching to a low-nicotine product.
Andersson G; Axéll T; Curvall M
J Oral Pathol Med; 1995 Jul; 24(6):244-50. PubMed ID: 7562659
[TBL] [Abstract][Full Text] [Related]
22. An in Vitro Study of Constituents Released from Smokeless Tobacco Products into Human Saliva.
Guan S; Bush L; Ji H
J Anal Toxicol; 2022 Jul; 46(6):625-632. PubMed ID: 34155520
[TBL] [Abstract][Full Text] [Related]
23. Surveillance of smokeless tobacco nicotine, pH, moisture, and unprotonated nicotine content.
Richter P; Spierto FW
Nicotine Tob Res; 2003 Dec; 5(6):885-9. PubMed ID: 14668072
[TBL] [Abstract][Full Text] [Related]
24. An approach for the extract generation and toxicological assessment of tobacco-free 'modern' oral nicotine pouches.
E B; N E; S B; S S; D S; M T; S M; A B; D B; D T; M G
Food Chem Toxicol; 2020 Nov; 145():111713. PubMed ID: 32998027
[TBL] [Abstract][Full Text] [Related]
25. Chemical and toxicological characterization of commercial smokeless tobacco products available on the Canadian market.
Rickert WS; Joza PJ; Trivedi AH; Momin RA; Wagstaff WG; Lauterbach JH
Regul Toxicol Pharmacol; 2009 Mar; 53(2):121-33. PubMed ID: 19135498
[TBL] [Abstract][Full Text] [Related]
26. Assessing the nicotine content of smokeless tobacco products.
Tilashalski K; Rodu B; Mayfield C
J Am Dent Assoc; 1994 May; 125(5):590-2, 594. PubMed ID: 8195501
[TBL] [Abstract][Full Text] [Related]
27. Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice.
Stenström B; Zhao CM; Rogers AB; Nilsson HO; Sturegård E; Lundgren S; Fox JG; Wang TC; Wadström TM; Chen D
Carcinogenesis; 2007 Sep; 28(9):2041-6. PubMed ID: 17389611
[TBL] [Abstract][Full Text] [Related]
28. Decreased levels of tobacco-specific N-nitrosamines in moist snuff on the Swedish market.
Osterdahl BG; Jansson C; Paccou A
J Agric Food Chem; 2004 Aug; 52(16):5085-8. PubMed ID: 15291479
[TBL] [Abstract][Full Text] [Related]
29. A qualitative and quantitative risk assessment of snuff dipping.
Nilsson R
Regul Toxicol Pharmacol; 1998 Aug; 28(1):1-16. PubMed ID: 9784428
[TBL] [Abstract][Full Text] [Related]
30. Analysis of 23 polycyclic aromatic hydrocarbons in smokeless tobacco by gas chromatography-mass spectrometry.
Stepanov I; Villalta PW; Knezevich A; Jensen J; Hatsukami D; Hecht SS
Chem Res Toxicol; 2010 Jan; 23(1):66-73. PubMed ID: 19860436
[TBL] [Abstract][Full Text] [Related]
31. Use of Scandinavian moist smokeless tobacco (snus) and the risk of atrial fibrillation.
Hergens MP; Galanti R; Hansson J; Fredlund P; Ahlbom A; Alfredsson L; Bellocco R; Eriksson M; Fransson EI; Hallqvist J; Jansson JH; Knutsson A; Pedersen N; Lagerros YT; Ostergren PO; Magnusson C
Epidemiology; 2014 Nov; 25(6):872-6. PubMed ID: 25166877
[TBL] [Abstract][Full Text] [Related]
32. Factors effecting the induction of rat forestomach hyperplasia induced by Swedish oral smokeless tobacco (snus).
Joksić G; Rutqvist LE; Mićić M; Tričković JF; Nilsson R
Regul Toxicol Pharmacol; 2019 Jun; 104():21-28. PubMed ID: 30844416
[TBL] [Abstract][Full Text] [Related]
33. Tobacco-related exposures: smokeless tobacco.
National Toxicology Program
Rep Carcinog; 2011; 12():412-4. PubMed ID: 21863110
[No Abstract] [Full Text] [Related]
34. [Harm reduction strategy in tobacco control].
Gorini G
Epidemiol Prev; 2011; 35(3-4 Suppl 1):19-32. PubMed ID: 21926451
[TBL] [Abstract][Full Text] [Related]
35. Determination of nicotine, pH, and moisture content of six U.S. commercial moist snuff products--Florida, January-February 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 May; 48(19):398-401. PubMed ID: 10366135
[TBL] [Abstract][Full Text] [Related]
36. Comparative in vitro toxicity profile of electronic and tobacco cigarettes, smokeless tobacco and nicotine replacement therapy products: e-liquids, extracts and collected aerosols.
Misra M; Leverette RD; Cooper BT; Bennett MB; Brown SE
Int J Environ Res Public Health; 2014 Oct; 11(11):11325-47. PubMed ID: 25361047
[TBL] [Abstract][Full Text] [Related]
37. Smokeless tobacco products harbor diverse bacterial microbiota that differ across products and brands.
Smyth EM; Kulkarni P; Claye E; Stanfill S; Tyx R; Maddox C; Mongodin EF; Sapkota AR
Appl Microbiol Biotechnol; 2017 Jul; 101(13):5391-5403. PubMed ID: 28432442
[TBL] [Abstract][Full Text] [Related]
38. Free nicotine content and strategic marketing of moist snuff tobacco products in the United States: 2000-2006.
Alpert HR; Koh H; Connolly GN
Tob Control; 2008 Oct; 17(5):332-8. PubMed ID: 18669556
[TBL] [Abstract][Full Text] [Related]
39. Monitoring tobacco-specific N-nitrosamines and nicotine in novel smokeless tobacco products: findings from round II of the new product watch.
Stepanov I; Biener L; Yershova K; Nyman AL; Bliss R; Parascandola M; Hatsukami DK
Nicotine Tob Res; 2014 Aug; 16(8):1070-8. PubMed ID: 24604020
[TBL] [Abstract][Full Text] [Related]
40. Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus.
Stepanov I; Jensen J; Biener L; Bliss RL; Hecht SS; Hatsukami DK
Nicotine Tob Res; 2012 Oct; 14(10):1241-5. PubMed ID: 22259150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
